7.08
Schlusskurs vom Vortag:
$7.30
Offen:
$7.27
24-Stunden-Volumen:
13.23M
Relative Volume:
0.36
Marktkapitalisierung:
$7.31B
Einnahmen:
$113.29M
Nettoeinkommen (Verlust:
$-351.47M
KGV:
-18.16
EPS:
-0.3898
Netto-Cashflow:
$-309.19M
1W Leistung:
+6.31%
1M Leistung:
-18.34%
6M Leistung:
+179.84%
1J Leistung:
+150.18%
Immunitybio Inc Stock (IBRX) Company Profile
Firmenname
Immunitybio Inc
Sektor
Branche
Telefon
(844) 696-5235
Adresse
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
IBRX
Immunitybio Inc
|
7.08 | 7.54B | 113.29M | -351.47M | -309.19M | -0.3898 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Fortgesetzt | BTIG Research | Buy |
| 2025-05-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | BTIG Research | Buy |
| 2023-05-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
ImmunityBio And 2 Insider Picks For Promising Growth - simplywall.st
FDA issues warning letter to ImmunityBio over misleading promotion of NAI - Urology Times
FDA Flags Anktiva Claims While ImmunityBio Pushes Regulatory Fixes - Benzinga
IBRX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - stocktwits.com
ImmunityBio Addresses FDA Warning on ANKTIVA Promotion - tipranks.com
ImmunityBio (IBRX) Stock Gains 3% Following FDA Compliance Response on Anktiva Marketing - Blockonomi
ImmunityBio submits response to FDA OPDP, removes podcast and strengthens promotional compliance - TradingView
ImmunityBio responds to FDA promotional compliance concerns By Investing.com - Investing.com India
ImmunityBio (NASDAQ: IBRX) outlines response to FDA ad concerns - Stock Titan
ImmunityBio (IBRX) Stock Climbs 3% After Firing Back at FDA Over Anktiva Ad Concerns - CoinCentral
ImmunityBio stock rises after FDA compliance response By Investing.com - Investing.com Canada
ImmunityBio addresses FDA correspondence and reaffirms commitment to advertising compliance - marketscreener.com
Immunitybio Addresses FDA Correspondence And Reaffirms Commitment To Advertising Compliance - TradingView
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance - Business Wire
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - The Killeen Daily Herald
Securing Non-Dilutive Funding to Support Immunotherapy Platform Growth – ImmunityBio - Oncodaily
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Black Hills Pioneer
CG Oncology: Passing A Red Line For What I Would Call A Reasonable Valuation (Downgrade) - Seeking Alpha
IBRX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio - gurufocus.com
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Snowflake Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. - globenewswire.com
ImmunityBio, Keysight, Rubrik, AFLAC, Moody’s Insider Shake-Up - TipRanks
IBRX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - Morningstar
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit - Sahm
Investors with Substantial Losses in ImmunityBio (IBRX) Have Opportunity to Lead Class Action Lawsuit - National Today
INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
IBRX INVESTOR ALERT: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - PR Newswire
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc.IBRX - PR Newswire
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - Carroll County Mirror-Democrat
When a podcast becomes promotion: Inside the FDA’s warning shot at ImmunityBio - Medical Marketing and Media
ImmunityBio, Inc. (IBRX) Class Action Lawsuit: Investors Face May 26, 2026, Deadline - PR Newswire
ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Jim Cramer on ImmunityBio: "I would encourage you to own it, provided you don’t own any other spec" - MSN
ImmunityBio Sued for Securities Law Violations - National Today
ImmunityBio Faces Investor Lawsuit Over Cancer Drug Claims - AD HOC NEWS
ImmunityBio (IBRX) insider converts $25M note into 4.6M shares - Stock Titan
IBRX SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of ImmunityBio, Inc. Investors - GlobeNewswire Inc.
ImmunityBio (NASDAQ:IBRX) Trading 2.2% HigherTime to Buy? - MarketBeat
ImmunityBio: No Need To Rush Into Buying TodayWhy I'm Downgrading To Hold (NASDAQ:IBRX) - Seeking Alpha
NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces - globenewswire.com
IMMUNITYBIO, INC. (IBRX) SHAREHOLDER ALERT Bernstein - globenewswire.com
ImmunityBio Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
IBRX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of ... - Bluefield Daily Telegraph
IBRX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming DeadlinesIBRX - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Investors to Connect - ACCESS Newswire
ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost — Hagens Berman - Morningstar
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed By the Firm - Morningstar
Finanzdaten der Immunitybio Inc-Aktie (IBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunitybio Inc-Aktie (IBRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Selecky Christobel | Director |
Feb 23 '26 |
Option Exercise |
2.98 |
25,000 |
74,500 |
25,000 |
| Selecky Christobel | Director |
Feb 23 '26 |
Sale |
10.00 |
25,000 |
250,000 |
0 |
| Sachs David C. | Chief Financial Officer |
Feb 22 '26 |
Option Exercise |
0.00 |
40,650 |
0 |
320,825 |
| SOON-SHIONG PATRICK | See remarks |
Feb 22 '26 |
Option Exercise |
0.00 |
114,329 |
0 |
29,816,081 |
| LAUER REGAN J | Chief Accounting Officer |
Feb 22 '26 |
Option Exercise |
0.00 |
4,065 |
0 |
117,548 |
| Adcock Richard | CEO & President |
Feb 22 '26 |
Option Exercise |
0.00 |
152,439 |
0 |
637,904 |
| Simon Barry J. | Director |
Feb 22 '26 |
Option Exercise |
0.00 |
15,243 |
0 |
3,096,847 |
| Simon Barry J. | Director |
Feb 23 '26 |
Sale |
10.25 |
165,000 |
1,691,102 |
2,925,821 |
| Simon Barry J. | Director |
Feb 20 '26 |
Sale |
9.25 |
10,000 |
92,500 |
3,081,604 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):